Dr Ammira AKIL 

Dr. Akil holds a leadership role at Sidra Medicine’s Metabolic and Mendelian Clinical Genomic Research Program and serves as Lead Principal Investigator for the Precision OMICs Research & Translational Medicine initiative in Doha, Qatar. Her extensive contributions to clinical genomic research, particularly in rare and complex metabolic diseases, are supported by her expertise in population-based research, cohort design, and the development of innovative screening initiatives.

As a visionary leader, Dr. Akil has played a pivotal role in securing over $7 million in research funding from prestigious national and international organizations. Her strategic approach to grant acquisition has led to successful collaborations with funding bodies, biotech companies, and pharmaceutical firms, driving groundbreaking research initiatives in genomic medicine.

Additionally, she has strengthened Sidra Medicine’s partnerships with the biotechnology and pharmaceutical industries, fostering collaborative projects that advance research and personalized healthcare. Her efforts have positioned Sidra Medicine as a key player in precision medicine research and specialized training in the region.

Dr. Akil has also made significant contributions to capacity building by training and mentoring hundreds of externs, equipping the next generation of researchers and clinicians with cutting-edge expertise in genomic medicine. Her dedication to developing a skilled workforce continues to impact the field on a regional and global scale.

She is an active member of several prestigious organizations, including the American Diabetes Association, the International Society for Pediatric and Adolescent Diabetes (ISPAD), the International Diabetes Society (IDS), the European Association for the Study of Diabetes (EASD), INNODIA—a global research consortium focused on advancing the understanding and treatment of Type 1 Diabetes and the ICoNS Consortium, the International Consortium on Newborn Sequencing.